Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia
Status:
Completed
Trial end date:
2019-07-31
Target enrollment:
Participant gender:
Summary
This is a two-stage adaptive Phase Ib trial design, that will identify two doses (lowest dose
with clinical benefit and highest safe dose) in a first stage and better evaluate safety,
tolerability and variability of effect in the second stage.